Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and dosimetry of Lutathera in adolescents with SSTR-positive GEP-NETs and PPGLs
2023-507444-37-00Phase 2Authorised
- Sponsor
- Advanced Accelerator Applications
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 5
01
Overview
Phase 2, open-label trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, pheochromocytoma and Paraganglioma (PGL) (2 cohorts), sponsored by Advanced Accelerator Applications. Primary endpoints: Target organ absorbed radiation doses after first Lutathera administration and Incidence of adverse events and laboratory toxicities after first Lutathera dose. Planned start Jul 2024; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid TumorpheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on 2023-507444-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507444-37-00.